Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India · Delayed Price · Currency is INR | Market Cap | 637.52B +60.6% |
| Revenue (ttm) | 165.10B +18.3% |
| Net Income | 10.65B |
| EPS | 37.74 |
| Shares Out | 282.20M |
| PE Ratio | 59.86 |
| Forward PE | 29.22 |
| Dividend | 5.00 (0.22%) |
| Ex-Dividend Date | n/a |
| Volume | 1,593,587 |
| Average Volume | 795,757 |
| Open | 2,390.00 |
| Previous Close | 2,393.00 |
| Day's Range | 2,226.30 - 2,413.90 |
| 52-Week Range | 1,370.00 - 2,474.00 |
| Beta | 0.31 |
| RSI | 44.66 |
| Earnings Date | May 29, 2026 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injec... [Read more]
Financial Performance
Financial StatementsNews
Top stocks for trade today, May 21: Ola Electric, Aditya Birla Capital, Jubilant FoodWorks, Apollo Hospitals, Glenmark Pharma and more
Several companies are likely to remain in focus on May 21 following quarterly earnings, fundraising announcements, order wins, project developments, and business updates. Ola Electric Shares of Ola El...
Glenmark Pharma shares in focus today after IGI unveils new cancer therapy candidate ISB 2301
Shares of Glenmark Pharmaceuticals are likely to remain in focus on Thursday after its innovation arm, Ichnos Glenmark Innovation (IGI), announced a new development candidate, ISB 2301, aimed at treat...
Glenmark unveils ISB 2301, a groundbreaking multispecific immune activator for solid tumours
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, has announced its latest development candidate, ISB 2301. This first-in-class, multispecific immune cells activat...
Pharma sector stocks today, April 29: Orchid Pharma surges 3.35%, Torrent Pharma up 1.78%, Glenmark Pharma rises 1.72%
The Indian pharmaceutical sector opened on a broadly positive note on April 29, 2026. Of the 24 pharma stocks tracked, the majority are trading in the green in early trade…
Pharma sector stocks today, April 28: Glenmark Pharma surge 1.80%, Strides Pharma down 2%, Indoco Remedies up 1.52%
Indian pharmaceutical stocks opened the session on April 28, 2026, with a mixed tone. The Nifty Pharma Index stood at 23,132.0, down 0.2% in early trade, while the broader S&P BSE Healthcare Index…
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Pharma sector stocks today, April 16: Ajanta Pharma down 1.53%, Glenmark Pharma falls 1.23%, Lupin drops 1.08%
The S&P BSE Healthcare index is marginally in the red at -0.10% in early trade, while broader markets (Sensex +0.52%, Nifty 50 +0.39%) are positive. Most losses in the pharma…
Glenmark Secures FDA Approval For Progesterone Vaginal Inserts, 100 Mg
(RTTNews) - Glenmark Pharmaceuticals Limited (532296) has received final approval from the U.S. FDA for its Progesterone Vaginal Inserts, 100 mg, marking a new addition to the company's women's health...
Pharma sector stocks today, April 9: Senores Pharma up 2.48%, Jubilant Pharmova down 2.02%, Glenmark Pharma falls 1.11%
The BSE Healthcare Index opened in positive territory on April 9, rising 0.40% to 42,261.7 even as the broader market slipped — the Sensex was down 0.70% and Nifty 50…
Glenmark Pharmaceuticals receives U.S. FDA approval for progesterone vaginal inserts
Glenmark Pharmaceuticals Limited has secured final approval from the United States Food & Drug Administration (U.S. FDA) for its Progesterone Vaginal Inserts, 100 mg. The FDA has determined these inse...
Pharma sector stocks rally sharply today, April 1: Marksans Pharma jumps 6%, Alembic gains 5.37%, Glenmark Pharma surge 4.30%
Indian pharma stocks showed broad-based gains in early trading on April 1, 2026. Many companies in the sector traded higher on both BSE and NSE, even as the broader market…
Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65%
The Indian pharmaceutical sector showed mixed movements in early trading, as of approximately 9:51 AM IST on March 24, 2026. The S&P BSE Healthcare Index stood at 41,630.4, reflecting a…
Pharma sector stocks today, March 23: Alembic Pharma down 2.24%, Ajanta Pharma falls 1.85%, Glenmark Pharma falls 1.98%
The pharmaceutical sector in India experienced a downturn on March 23, 2026, as reflected in early morning trading data from BSE and NSE around 9:29-9:30 AM IST. Most listed pharma…
Pharma sector stocks fall today, March 19: Biocon down 2.33%, Laurus Labs falls 2.29%, Glenmark Pharma drops 2%
Pharmaceutical stocks in India experienced a decline on March 19, 2026, during early trading hours. Market data as of approximately 9:46 AM IST (BSE) and 9:49 AM IST (NSE) showed…
Glenmark Pharmaceuticals launches authorised generic to Savella tablets in the US
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Milnacipran Hydrochloride Tablets in the US market. These tablets, available in dosage...
Glenmark Pharmaceuticals receives US FDA approval for Fluticasone Propionate Nasal Spray
Glenmark Pharmaceuticals Limited has announced that it has received final approval from the United States Food & Drug Administration (U.S. FDA) for its Fluticasone Propionate Nasal Spray USP, 50 mcg…
Pharma sector stocks today, March 16: Suven Life up 3.46%, Glenmark Pharma surge 1.39%, Divis Lab rises 0.36%
The pharmaceutical sector stocks in India showed mixed performance on March 16, 2026, during early trading hours. Data is based on prices as of approximately 9:43 AM IST for BSE…
Pharma sector stocks today, March 11: Natco Pharma falls 1.35%, Alembic Pharma surge 1.33%, Glenmark Pharma up 1.41%
The Pharmaceuticals sector stocks in India showed mixed performance on March 11, 2026, during early trading hours. Data is based on prices as of approximately 9:43 AM IST for BSE…
Pharma sector stocks surge today, March 10: Natco Pharma up 4%, Granules India jumps 3.31%, Glenmark Pharma rises 2.72%
The pharmaceutical sector in India showed positive movement on March 10, 2026, during early trading hours, with many stocks recording gains as of approximately 9:36 AM IST on BSE and…
Pharma sector fall sharply otday, March 9: Laurus Labs down 3%, Glenmark Pharma drops 2.44%, Zydus Life falls 2.10%
The Indian pharmaceutical sector experienced declines on March 9, 2026, amid broader market weakness. As of approximately 9:36-9:39 AM IST, most listed pharma stocks traded lower on both BSE and…
Glenmark Pharma subsidiary gets US FDA approves Fluticasone Propionate inhalation aerosol with 180-day exclusivity
Glenmark Pharmaceuticals is likely to remain in focus after its subsidiary, Glenmark Specialty SA, received final approval from the United States Food and Drug Administration (US FDA) for Fluticasone ...
Glenmark Pharma’s US arm to launch Sodium Phosphates Injection USP
Glenmark Pharmaceuticals Inc., the US arm of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Sodium Phosphates Injection USP...
Pharma sector stocks today, Feb 9: Marksans Pharma up 5%, Shilpa Medicare jumps 6%, Glenmark rises 1.83%
The Indian pharma sector showed mixed intraday movements on February 9, 2026, amid broader market gains driven by positive global...
Glenmark Pharmaceuticals Transcript: Q3 25/26
Q3 FY 2026 saw 15.1% YoY revenue growth, strong performance in India, North America, and Europe, and robust expansion of innovative assets. Margin profile remained healthy at 23%, with net cash position and working capital targets on track. Growth outlook is positive, driven by new launches and specialty products.
Glenmark Pharmaceuticals Quarterly report: Q3 2026
Glenmark Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 1, 2026.